

Speakers' Portal
IGCS18 CME Disclosure Form Results

<u>Last Name</u>	<u>First Name</u>	<u>Roles</u>	<u>Relationships</u>	<u>Company Name</u>	<u>Honoraria/ Expenses</u>	<u>Consulting/ Advisory Board</u>	<u>Funded Research</u>	<u>Royalties/ Patent</u>	<u>Stock Options</u>	<u>Ownership/ Equity Position</u>	<u>Employee</u>	<u>Other</u>	<u>Off Label Product Use</u>
Abu-Rustum	Nadeem	Invited Speaker/Faculty Session Moderator/Chair/Coordinator Board of Directors	No										
Adams	Tracey	Session Moderator/Chair/Coordinator	No										
Adams	Catherine	Invited Speaker/Faculty	No										
Amant	Frederic	Invited Speaker/Faculty	No										
Arimoto	Takahide	Invited Speaker/Faculty Poster/Oral Presenter	No										
Asada	Kayo	Invited Speaker/Faculty Poster/Oral Presenter	No										
Bacon	Monica	Invited Speaker/Faculty	No										
Baiocchi	Glauco	Invited Speaker/Faculty Poster/Oral Presenter	No										
Baker	Eilen	Invited Speaker/Faculty	No										
Becker	Sven	Invited Speaker/Faculty Poster/Oral Presenter	No										
Berek	Jonathan S.	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Tesaro			X						
Binagwaho	Agnes	Invited Speaker/Faculty	No										
Brand	Alison	Invited Speaker/Faculty	No										
Brennan	Donal	Session Moderator/Chair/Coordinator	No										
Chiang	Sarah	Invited Speaker/Faculty	No										
Cohen	Paul	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No										
Coleman	Robert L	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter	Yes	AstraZeneca	X	X	X						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Eisai	X	X	X						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Genentech	X	X	X						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Janssen Pharmaceuticals	X	X	X						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Novartis	X	X							bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Tesaro		X							bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Abbvie		X	X						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Clovis	X	X	X						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics

				Merck		X	X													bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics		
				Genmab	X	X	X													bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics		
Covens	Allan	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter	No																			
Creutzberg	Carien	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No																			
Dizon	Don	Invited Speaker/Faculty	No																			
Dreyer	Greta	Invited Speaker/Faculty Poster/Oral Presenter	No																			
Duska	Linda	Invited Speaker/Faculty	No																			
Eskander	Ramez	Invited Speaker/Faculty	Yes	AstraZeneca	X	X																
				Genentech	X	X																
				Clovis Oncology	X	X																
Ferron Fleming	Gwenaël Gini	Invited Speaker/Faculty	No																			
		Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes																			
Frumovitz	Michael	Invited Speaker/Faculty	Yes	Stryker	X	X	X															
				Navidea			X															
				Genentech			X															
Fujii	Shingo		No																			
Fujiwara	Noriko	Invited Speaker/Faculty	No																			
Fujiwara	Hiroyuki	Invited Speaker/Faculty	No																			
Fujiwara	Keiichi	Scientific/Education Planning Committee	Yes	AstraZeneca	X	X	X															
		Invited Speaker/Faculty		Daiichi Sankyo	X	X	X															
		Session Moderator/Chair/Coordinator		Eisai	X	X	X															
				Janssen Pharmaceuticals	X																	
				Merck		X	X															
				Pfizer		X	X															
				Takeda		X																
				Ono Pharmaceuticals		X	X															
				Zeria		X		X														
				Chugai Roche		X																
	Kyowahakko-Kirin		X																			
Gardner	Ginger	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No																			
Garrett	Andrea	Invited Speaker/Faculty	No																			
Gerda Zahl Eriksson	Ane	Session Moderator/Chair/Coordinator	No																			
Gershenson	David	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	celgene																	aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors	
				Johnson&Johnson																		aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors
				Biogen Idec																		aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors

				Clovis Oncology		X							aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors
				Elsevier				X					aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors
				UpToDate				X					aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors
				UT MD Anderson Cancer Center						X			aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors
				National Cancer Institute (NRG Oncology)			X						aromatase inhibitors, tamoxifen, leuprolide acetate, MEK inhibitors, CDK 4/6 inhibitors
Gilks	Blake	Invited Speaker/Faculty	No										
Gotlieb	Walter	Invited Speaker/Faculty Board of Directors	Yes	AstraZeneca		X	X						
Gourley	Charlie	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	AstraZeneca	X	X	X						A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products.
				Genentech	X	X							A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products.
				Nucana	X	X	X						A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products.
				Tesaro	X	X	X						A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products.
				Novartis			X						A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products.

Nout	Remi	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No																			
Oaknin	Ana	Session Moderator/Chair/Coordinator	Yes	AstraZeneca		X																
				Tesaro		X																
				Hoffmann-La Roche		X																
Oda	Mizue	Poster/Oral Presenter	No																			
Oda	Katsutoshi	Invited Speaker/Faculty	No																			
Ohno	Tatsuya	Invited Speaker/Faculty	No																			
Okamoto	Aikou	Scientific/Education Planning Committee Session Moderator/Chair/Coordinator	Yes	Daiichi Sankyo				X														
				Novartis				X														
				Pfizer				X														
Olawaiye	Alexander	Scientific/Education Planning Committee Invited Speaker/Faculty	Yes	Janssen Pharmaceuticals				X														
				Tesaro																		
Orango	Elkanah Omenge	Invited Speaker/Faculty	No																			
Orlandini	Elisa	Invited Speaker/Faculty	No																			
Pareja	René	Session Moderator/Chair/Coordinator	No																			
Pearl	Michael	Invited Speaker/Faculty	Yes					VitaTex		X			X									
Plotti	Francesco	Session Moderator/Chair/Coordinator	No																			
Power	Joanne	Invited Speaker/Faculty	Yes	AstraZeneca	X	X																
Pujade- Lauraine	Eric	Invited Speaker/Faculty	Yes	AstraZeneca	X	X																
				AstraZeneca	X	X																
				Hoffmann-La Roche	X	X																
				Pfizer		X																
				Tesaro	X	X																
				Galileo		X																
Puntambekar Rimel	Shaelish Bobbie	Invited Speaker/Faculty Invited Speaker/Faculty	No Yes																			
				Tesaro				X														
		Genentech				X																
Sakamoto	Masaru	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No																			
Sato	Masakazu	Invited Speaker/Faculty	No																			
Sato	Seiya	Poster/Oral Presenter	No																			
Schmeler	Kathleen	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter Committee (CME Research other)	No																			
Scott	Clare	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	AstraZeneca		X		X														
				Eisai															Research Collaboration, drug support		pre-clinical use of PARP inhibitors and eribulin in ovarian cancer models	
				Clovis Oncology															Research Collaboration, drug support		pre-clinical use of PARP inhibitors and eribulin in ovarian cancer models	
				Sierra Oncology						X												pre-clinical use of PARP inhibitors and eribulin in ovarian cancer models
				BeiGene																Research Collaboration, drug support		pre-clinical use of PARP inhibitors and eribulin in ovarian cancer models

